Compare · AKER vs ORKA
AKER vs ORKA
Side-by-side comparison of Akers Biosciences Inc. (AKER) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKER and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $3.86B.
- ORKA has hit the wire 11 times in the past 4 weeks while AKER has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for AKER).
- Company
- Akers Biosciences Inc.
- Oruka Therapeutics Inc.
- Price
- -
- $63.52-0.80%
- Market cap
- -
- $3.86B
- 1M return
- -
- -1.63%
- 1Y return
- -
- +405.33%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
Latest AKER
- SEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)
- SEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock
- SEC Form 4 filed by EAGLE CRAIG
- SEC Form 3 filed by EAGLE CRAIG
- Akers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Kaplin Adam
- SEC Form 3 filed by Kaplin Adam
- SEC Form 4: Schreiber Christopher C exercised 131,750 units of Common Stock at a strike of $0.00 and disposed of $227,798 worth of Common Stock (46,113 units at $4.94), increasing direct ownership by 3,292% to 88,238 units to cover withholding tax
- SEC Form 4 filed by Uzonwanne Jude
- SEC Form 4: Chapman Christopher C JR was granted 96,475 units of Common Stock
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)